ERIC PELFRENE

ERIC PELFRENE

orcid

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2015 in The Lancet Infectious Diseases
Verified
Journal Article
Closed access
JCJonathan Cohen
Jonathan Cohen
JVJean-Louis Vincent
Jean-Louis Vincent
NANeill K J Adhikari
Neill K J Adhikari
FMFlavia R Machado
Flavia R Machado
DADerek C Angus
Derek C Angus
EPERIC PELFRENE
ERIC PELFRENE

10 April 2016 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Open access
PDF file
EPERIC PELFRENE
ERIC PELFRENE
EWElsa Willebrand
Elsa Willebrand
ASAna Cavaleiro Sanches
Ana Cavaleiro Sanches
ZSZigmars Sebris
Zigmars Sebris
MCMarco Cavaleri
Marco Cavaleri
Despite the recognized problem of antibiotic multidrug resistance, very few antibacterial agents with new mechanisms of action are under development. Bacteriophage therapy could offer one alternative strategy to mitigate this challenge. Although widely used throughout the 20th century in Eastern Europe and the former Soviet Union, this potential therapy has not yet been investigated according to rigorous scientific standards. This paper reports on a multistakeholder meeting held at the EMA, which outlined the existing regulatory framework to which such therapy should adhere and reviewed the current obstacles and shortcomings in scientific development for bacteriophage therapy.

29 January 2021 in Antimicrobial Resistance & Infection Control
Verified
Journal Article
Open access
PDF file
EPERIC PELFRENE
ERIC PELFRENE
RBRadu Botgros
Radu Botgros
MCMarco Cavaleri
Marco Cavaleri
Background: Antimicrobial resistance (AMR) is a growing global problem to which the ongoing COVID-19 pandemic may further contribute. With resources deployed away from antimicrobial stewardship, evidence of substantial pre-emptive antibiotic use in COVID-19 patients and indirectly, with deteriorating economic conditions fuelling poverty potentially impacting on levels of resistance, AMR threat remains significant. Main body: In this paper, main AMR countermeasures are revisited and priorities to tackle the issue are re-iterated. The need for collaboration is stressed, acknowledging the relationship between human health, animal health and environment (“One Health” approach). Among the stated priorities, the initiative by the European Medicines Regulatory Network to further strengthen the measures in combatting AMR is highlighted. Likewise, it is asserted that other emerging health threats require global collaboration with the One Health approach offering a valuable blueprint for action. Conclusion: The authors stress the importance of an integrated preparedness strategy to tackle this public health peril.

1 January 2019 in Clinical Microbiology and Infection
Verified
Journal Article
Closed access
EPERIC PELFRENE
ERIC PELFRENE
MMM. Mura
M. Mura
ASA. Cavaleiro Sanches
A. Cavaleiro Sanches
MCM. Cavaleri
M. Cavaleri

27 June 2019 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
EPERIC PELFRENE
ERIC PELFRENE
MAMartin Harvey Allchurch
Martin Harvey Allchurch
NNNsengi Ntamabyaliro
Nsengi Ntamabyaliro
VNVictoria Nambasa
Victoria Nambasa
FVFátima V Ventura
Fátima V Ventura
MCMarco Cavaleri
Marco Cavaleri

31 July 2016 in Clinical Infectious Diseases
Verified
Journal Article
Closed access
PDF file
CKCharles Knirsch
Charles Knirsch
DADemissie Alemayehu
Demissie Alemayehu
RBRadu Botgros
Radu Botgros
SCSabrina Comic-Savic
Sabrina Comic-Savic
DFDavid Friedland
David Friedland
VFVance G Fowler
Vance G Fowler
Background. The etiology of hospital-acquired or ventilator-associated bacterial pneumonia (HABP/VABP) is often multidrug-resistant infections. The evaluation of new antibacterial drugs for efficacy in this population is important, as many antibacterial drugs have demonstrated limitations when studied in this population. HABP/VABP trials are expensive and challenging to conduct due to protocol complexity and low patient enrollment, among other factors. The Clinical Trials Transformation Initiative (CTTI) seeks to advance antibacterial drug development by streamlining HABP/VABP clinical trials to improve efficiency and feasibility while maintaining ethical rigor, patient safety, information value, and scientific validity. Methods. In 2013, CTTI engaged a multidisciplinary group of experts to discuss challenges impeding the conduct of HABP/VABP trials. Separate workstreams identified challenges associated with HABP/VABP protocol complexity. The Project Team developed potential solutions to streamline HABP/VABP trials using a Quality by Design approach. Results. CTTI recommendations focus on 4 key areas to improve HABP/VABP trials: informed consent processes/practices, protocol design, choice of an institutional review board (IRB), and trial outcomes. Informed consent processes should include legally authorized representatives. Protocol design decisions should focus on eligibility criteria, prestudy antibacterial therapy considerations, use of new diagnostics, and sample size. CTTI recommends that sponsors use a central IRB and discuss trial endpoints with regulators, including defining a clinical failure and evaluating the impact of concomitant antibacterial drugs. Conclusions. Streamlining HABP/VABP trials by addressing key protocol elements can improve trial startup and patient recruitment/retention, reduce trial complexity and costs, and ensure patient safety while advancing antibacterial drug development.